Search clinical trials for: Normal hepatic function

Total 33473 results

Bayer

Recruiting

A Study to Learn About How BAY 3283142 Moves Into, Through, and Out of the Body After a Single Dose in Participants With Reduced Liver Function Compared to Participants With Normal Liver Function

Chronic Kidney Disease | Hepatic Impairment

United States
NewAmsterdam Pharma
Veranex

Recruiting

PK and Safety in Participants Taking Obicetrapib With Moderate Hepatic Impairment Relative to Normal Hepatic Function

Healthy | Hepatic Impairment

United States
Novo Nordisk A/S

Recruiting

A Research Study Looking at How a Single Dose of the Study Medicine NNC0194-0499 Behaves in Participants With Reduced Liver Function Compared to Participants With Normal Liver Function

Healthy Volunteers | Hepatic Impairment

Germany, Poland, Slovakia
Eli Lilly and Company

Recruiting

A Study of LY3437943 in Participants With Impaired and Normal Liver Function

Hepatic Insufficiency | Healthy

United States
Eli Lilly and Company

Recruiting

A Study of LY3502970 in Participants With Impaired and Normal Liver Function

Hepatic Insufficiency | Healthy

United States
Daewoong Pharmaceutical Co. LTD.

Recruiting

To Compare the Safety and PK/PD Characteristics of Subjects With Between Hepatic Impairment and Normal Hepatic Function

Diabetes Mellitus, Type 2

Korea, Republic of
Atea Pharmaceuticals, Inc.

Recruiting

Study of Bemnifosbuvir in Subjects With Normal and Impaired Hepatic Function

Hepatic Impairment | Healthy Volunteer

United States
Novo Nordisk A/S

Recruiting

A Research Study Looking at How a Single Dose of the Medicine Cagrilintide Behaves in Participants With Reduced Liver Function and in Healthy Participants With Normal Liver Function

Hepatic Impairment

Germany, Slovakia
Bristol-Myers Squibb

Recruiting

A Study to Evaluate CC-486/Onureg in Participants With Moderate or Severe Hepatic Impairment Compared With Normal Hepatic Function in Participants With Myeloid Malignancies

Hepatic Insufficiency | Neoplasms

Spain, United States, Germany, Argentina, Colombia, Greece
Zydus Therapeutics Inc.

Recruiting

Hepatic Impairment, Cholestatic Liver Disease, & NASH With Advanced Fibrosis & Normal Hepatic Function

Hepatic Impairment

United States
GlaxoSmithKline

Recruiting

A Study of Belantamab Mafodotin in Multiple Myeloma Participants With Normal and Impaired Hepatic Function (DREAMM 13)

Multiple Myeloma

Greece, Korea, Republic of, United States
Epizyme, Inc.
Sponsor GmbH

Recruiting

A Study to Compare the Blood Levels and Safety of Tazemetostat in Participants With Advanced Cancer and Moderate/Severe Liver Impairment to Participants With Advanced Cancer and Normal Liver Function

Hepatic Impairment | Advanced Malignant Solid Tumor

France, Belgium, United States, Poland, Slovakia
Janssen Research & Development, LLC

Recruiting

A Study of Apalutamide in Participants With Severe Hepatic Impairment Compared With Participants With Normal Hepatic Function

Hepatic Impairment

United States
Lykos Therapeutics

Not yet recruiting

MDMA in Subjects With Moderate Hepatic Impairment and Subjects With Normal Hepatic Function

Pharmacokinetics | Hepatic Impairment

United States
Chipscreen Biosciences, Ltd.

Completed

Pharmacokinetics of Chiglitazar in Subjects With Hepatic Impairment and Normal Hepatic Function

Hepatic Impairment

China
Incyte Corporation

Completed

A Study to Evaluate the Pharmacokinetics and Safety of INCB054707 in Participants With Normal Hepatic Function and Participants With Hepatic Impairment

Kidney Diseases | Renal Insufficiency

United States, Germany
SK Life Science, Inc.

Completed

Safety Study of Cenobamate in Subjects With Normal Hepatic Function and Subjects With Severe Hepatic Impairment

Hepatic Impairment

Poland, Slovakia
Astellas Pharma Global Development, Inc.

Completed

A Study to Investigate the Effect of Mild and Moderate Hepatic Impairment on the Safety and Tolerability of Fezolinetant Compared to Participants With Normal Hepatic Function

Healthy Volunteers | Hepatic Impairment

United States
Institut de Recherches Internationales Servier

Completed

A Study of Vorasidenib in Participants With Moderate or Mild Hepatic Impairment and Matched Participants With Normal Hepatic Function

Hepatic Impairment

United States
Sanofi

Completed

A Study in Adults to Investigate the Impact of Mild, Moderate, and Severe Hepatic Impairment on Pharmacokinetics of Venglustat Compared to Participants With Normal Hepatic Function

Hepatic Function Abnormal

United States, Germany
Takeda

Completed

A Study of Soticlestat in Adults With Liver Failure Compared to Those With Normal Liver Function

Healthy Volunteers | Hepatic Impairment

United States, Hungary
Reata, a wholly owned subsidiary of Biogen

Completed

A Pharmacokinetic Study of Omaveloxolone in Subjects With Hepatic Impairment and Normal Hepatic Function

Hepatic Impairment

United States
Reata, a wholly owned subsidiary of Biogen

Completed

Single-Dose, Open-Label Pharmacokinetic Study of Bardoxolone Methyl in Subjects With Mild, Moderate, and Severe Hepatic Impairment and Normal Hepatic Function

Healthy | Hepatic Impairment

United States
Suzhou Zelgen Biopharmaceuticals Co.,Ltd

Completed

Pharmacokinetics Of Jaktinib In Subjects With Hepatic Impairment And Normal Hepatic Function

Hepatic Insufficiency | Healthy Subjects

China
Sagimet Biosciences Inc.

Completed

A Phase I Pharmacokinetic Study of TVB-2640 (Denifanstat) in Subjects With Mild, Moderate, or Severe Hepatic Impairment Compared to Subjects With Normal Hepatic Function

Cirrhosis | Hepatic Impairment | Non-alcoholic Steatohepatitis

United States, Hungary
Millennium Pharmaceuticals, Inc.

Completed

A Study to Evaluate Pharmacokinetics (PK) and Safety of Oral Mobocertinib in Participants With Moderate or Severe Hepatic Impairment (HI) and Normal Hepatic Function

Healthy Volunteers | Hepatic Impairment

United States
Amgen

Completed

A Study to Evaluate the Pharmacokinetics, Safety, and Pharmacodynamics of Olpasiran in Participants With Various Degrees of Hepatic Impairment

Hepatic Impairment

United States
Agios Pharmaceuticals, Inc.

Completed

A Pharmacokinetic Study of Mitapivat in Participants With Moderate Hepatic Impairment Compared to Matched Healthy Control Participants With Normal Hepatic Function

Moderate Hepatic Impairment

United States
Bayer

Completed

A Study to Learn How the Study Treatment Asundexian Moves Into, Through and Out of the Body, How it Works, How Safe it is, and How it Affects the Body in Participants With Mild or Moderate Reduction of Liver Function Compared to Participants With Normal Liver Function

Atrial Fibrillation | Hepatic Impairment | Acute Myocardial Infarction | Prevention of Thromboembolic Events | Non-cardioembolic Ischemic Stroke

Germany
VectivBio AG

Completed

A Phase 1, Open-Label Evaluation of the Pharmacokinetics and Safety of a Single Dose of Apraglutide in Subjects With Normal and Impaired Hepatic Function

Hepatic Impairment

Germany, Slovakia
Novartis Pharmaceuticals

Completed

Pharmacokinetic (PK) and Safety Study of Iptacopan (LNP023) in Participants With Mild, Moderate, and Severe Hepatic Impairment Compared to Matched Control Healthy Participants With Normal Hepatic Function.

Hepatic Impairment

United States
Insmed Incorporated

Completed

A Study to Evaluate the Pharmacokinetics (PK) and Safety of a Single Dose of Brensocatib in Participants With Normal Hepatic Function and Participants With Hepatic Impairment

Hepatic Impairment

United States
Cerevel Therapeutics, LLC

Completed

To Evaluate the Pharmacokinetics (PK) and Safety of Tavapadon in Participants With Mild and Moderate Hepatic Impairment Compared to Participants With Normal Hepatic Function

Hepatic Impairment

United States
Mitsubishi Tanabe Pharma America Inc.

Completed

Study to Assess Pharmacokinetics, Safety, and Tolerability of MT-7117 in Subjects With Normal and Impaired Hepatic Function

Mild and Moderate Hepatic Impairment

United States
Astellas Pharma Global Development, Inc.

Completed

A Study to Evaluate ASP0367 in Participants With Mild/Moderate Hepatic Impairment Compared to Participants With Normal Hepatic Function

Healthy Volunteers | Hepatic Impairment

United States
Bayer

Completed

Study on the Safety of BAY1817080, How it is Tolerated and the Way the Body Absorbs, Distributes and Gets Rid of the Study Drug in Participants With Impaired Liver Function or Normal Liver Function

Overactive Bladder | Diabetic Neuropathic Pain | Endometriosis Related Pain | Refractory or Unexplained Chronic Cough

United States
Sanofi

Completed

Study to Assess the Plasma Concentration of Tolebrutinib Given as a Tablet to Adult Participants With Mild Hepatic Impairment Compared to Participants With Normal Hepatic Function

Hepatic Function Abnormal

United States, Belgium
Sanofi

Terminated

Pharmacokinetics of Amcenestrant in Female Hepatic Impaired Participants as Compared to Participants With Normal Hepatic Function

Hepatic Function Abnormal

Korea, Republic of, Germany
Incyte Corporation

Completed

To Evaluate the Safety, and Pharmacokinetics of Parscaclisib in Participants With Normal Hepatic Function and Hepatic Impairment.

Advanced Malignancies

United States
Kadmon, a Sanofi Company

Completed

KD025 Hepatic Impairment Study With Normal Hepatic Function and Subjects With Varying Degrees of Hepatic Impairment

Hepatic Impairment

United States
Bristol-Myers Squibb

Completed

A Study to Evaluate the Drug Levels, Safety, and Tolerability of BMS-986036 in Participants With Normal Liver Function and Participants With Moderate and Severe Liver Impairment

Moderate Liver Impairment | Severe Liver Impairment

United States
Galectin Therapeutics Inc.

Completed

A Single-dose, Open-label, Pharmacokinetic Study of Belapectin (GR-MD-02) in Subjects With Normal Hepatic Function and Subjects With Varying Degrees of Hepatic Impairment

Hepatic Impairment

United States
Vigonvita Life Sciences
Shanghai Institute of Materia Medica, Chinese Academy of Sciences

Completed

Study of the Pharmacokinetics and Safety of TPN171H Tablets in Subjects With Mild ,Moderate Hepatic Insufficiency and Normal Liver Function

Erectile Dysfunction | Pulmonary Arterial Hypertension

China
UCB Biopharma S.P.R.L.

Terminated

A Pharmacokinetic Study of Padsevonil in Study Participants With Either Normal or Moderately Impaired Hepatic Function

Impaired Hepatic Function | Healthy Study Participants

United States
Novartis Pharmaceuticals

Completed

PK and Safety of Midostaurin in Subjects With Impaired Hepatic Function and Subjects With Normal Hepatic Function

Hepatic Impairment

Germany, Belgium, Lithuania, United States, Bulgaria, Romania
GlaxoSmithKline
Biomedical Advanced Research and Development Authority

Completed

Pharmacokinetics (PK) Study of Gepotidacin (GSK2140944) in Adult Subjects With Varying Degrees of Hepatic Impairment and in Matched Control Subjects With Normal Hepatic Function

Infections, Bacterial

United States
Hoffmann-La Roche

Completed

A Study to Investigate the Effect of Hepatic Impairment on the Pharmacokinetics and Safety and Tolerability of a Single Oral Dose of Risdiplam Compared to Matched Healthy Participants With Normal Hepatic Function

Muscular Atrophy, Spinal

United States
Gilead Sciences

Completed

Study to Evaluate the Pharmacokinetics of Selonsertib in Participants With Normal and Impaired Hepatic Function

Diabetic Kidney Disease

United States
Gilead Sciences

Completed

Pharmacokinetics and Pharmacodynamics of Cilofexor in Adults With Normal and Impaired Hepatic Function

Nonalcoholic Steatohepatitis (NASH) | Primary Sclerosing Cholangitis (PSC)

United States, New Zealand
Novartis Pharmaceuticals

Completed

Pharmacokinetics (PK) of TKI258 in Cancer Patients With Normal and Impaired Hepatic Function

Hepatic Impairment | Solid Tumors

Belgium, Germany, Netherlands, Italy, Singapore, United States

3

Subscribe